Shionogi Expands Fetroja Role in U.S. Drug-Resistance Preparedness
Osaka, Japan – August 28, 2026 Shionogi & Co., Ltd. announced that the Biomedical Advanced Research and Development Authority...
VABP
Advertisement
FDA Accepts Shionogi’s sNDA for Fetroja in Pediatric Gram-Negative Infections
FLORHAM PARK, N.J., July 16, 2026 Shionogi Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Telum Therapeutics Raises €18M Series A for AMR Program
SPAIN, July 1, 2026 Telum Therapeutics announced the successful completion of an €18 million Series A financing round to...
Innoviva and Dr. Reddy’s Expand Global Access to XACDURO®
WALTHAM, Mass., June 16, 2026 Innoviva Specialty Therapeutics announced an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories...
BioVersys Starts Phase 3 BV100 Pneumonia Trial
BASEL, Switzerland, April 16, 2026 BioVersys AG has announced a key clinical milestone with the first patient first visit...
Advertisement
